Multiple myeloma remains one of the most challenging hematologic cancers. However, significant progress over recent decades has transformed the treatment paradigm, offering hope for patients through a combination of established methods and groundbreaking therapies. This article delves into the evolution of multiple myeloma treatment, emphasizing the need for a personalized and adaptive approach tailored to each patient's disease profile.

Conventional Chemotherapy

Historically, chemotherapy was the primary treatment for multiple myeloma. Although effective at reducing tumor load, it often came with substantial side effects and limited long-term remission. Patients frequently experienced relapses, prompting the development of more targeted approaches.

Stem Cell Transplantation as a Standard of Care

High-dose chemotherapy followed by autologous stem cell transplantation revolutionized management, significantly improving survival rates. Yet, not all patients are eligible due to age or comorbidities, necessitating alternative strategies.

Proteasome Inhibitors and Immunomodulatory Drugs

Agents such as bortezomib, lenalidomide, and pomalidomide have become mainstays in treatment, offering potent anti-myeloma activity with manageable toxicity. Their combination has enhanced response rates and extended progression-free survival.

Monoclonal Antibodies and Immune Modulators

Drugs like daratumumab target specific surface proteins on myeloma cells, triggering immune-mediated destruction. These therapies are increasingly used in both frontline and relapsed settings.

Chimeric Antigen Receptor (CAR) T-Cell Therapy

As a revolutionary form of immunotherapy, CAR T-cell therapy involves genetically modifying a patient’s T cells to target myeloma-specific antigens, showing remarkable results in relapsed/refractory cases.

Novel Pharmacological Agents

Next-generation drugs such as selinexor and bispecific antibodies are expanding the therapeutic arsenal, offering options for resistant disease.

Personalized Medicine and Biomarker-Driven Treatments

Understanding the genetic makeup of an individual's tumor aids in customizing therapy plans, maximizing benefits and reducing adverse effects.

Continuous research and clinical trials drive innovation in multiple myeloma treatment. Patients and clinicians must stay informed about emerging options to optimize outcomes and quality of life. Addressing the disease with an evidence-based, personalized approach remains essential in the journey toward better survival and well-being.